| Literature DB >> 29121636 |
A M Witkowski1, J Łudzik1,2, F Arginelli1, S Bassoli1, E Benati1, A Casari1, N De Carvalho1, B De Pace1, F Farnetani1, A Losi1, M Manfredini1, C Reggiani1, J Malvehy3, G Pellacani1.
Abstract
BACKGROUND: Reflectance confocal microscopy (RCM) is an imaging device that permits non-invasive visualization of cellular morphology and has been shown to improve diagnostic accuracy of dermoscopically equivocal cutaneous lesions. The application of double reader concordance evaluation of dermoscopy-RCM image sets in retrospective settings and its potential application to telemedicine evaluation has not been tested in a large study population.Entities:
Mesh:
Year: 2017 PMID: 29121636 PMCID: PMC5679638 DOI: 10.1371/journal.pone.0187748
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Previous studies evaluating the accuracy of reflectance confocal microscopy.
| ref. n. | First Author, year | Journal | Country | Setting | Total lesion number | Malignancies | Sensitivity | Specificity | Study population | Diagnostic reference |
|---|---|---|---|---|---|---|---|---|---|---|
| 5 | Łudzik, 2016 | PLoS One | Poland, Italy | Retrospective | 316 | 12 MMs, 138 BCCs, 20 SCCs | 94% (Double reading 98%) | 54% (Double reading 42%) | Pink lesions | Histopathology + ≥1 year follow-up |
| 6 | Borsari, 2016 | JAMA Dermatol | Italy | 1279 | 246 MMs, 61 BCCs, 16 SCCs | 97% | 62% | Dermoscopically equivocal, any type | Histopathology + ≥1 year follow-up | |
| 7 | Guitera, 2016 | Br J Dermatol | Australia, Italy | Retrospective | 191 | 45 MMs, 48 BCCs, 10 SCCs | 84% | 47% | Pink lesions | Histopathology |
| 8 | Stanganelli, 2016 | J Eu Acad Dermatol Venereol | Spain | Retrospective | 70 | 12 MMs | 92% | 46% | Melanocytic lesions changing at sequential digital dermoscopy | Histopathology |
| 9 | Lovatto, 2016 | Br J Dermatol | Italy | Retrospective | 64 | 13 MMs | 100% | 69% | Melanocytic lesions changing at sequential digital dermoscopy | Histopathology |
| 10 | Farnetani, 2015 | JAMA Dermatol | International | Retrospective | 100 | 20 MMs, 15 BCCs | 89% (Majority 100%) | 79% (Majority 80%) | Selected lesions evaluated by 9 evaluators | Histopathology |
| 11 | Pellacani, 2015 | Br J Dermatol | Italy | 493 | 29 MMs, 39 BCCs | 100% | 47% | Dermoscopically equivocal lesions, any type | Histopathology + ≥1 year follow-up | |
| 12 | Alarcon, 2015 | Br J Dermatol | Spain | 343 | 92 MMs | 100% | 31% | Dermoscopically equivocal melanocytic lesions | Histopathology + ≥1 year follow-up | |
| 13 | Ferrari, 2014 | J Eu Acad Dermatol Venereol | Italy | Retrospective | 322 | 70 MMs | 96% | 70% | Dermoscopically equivocal melanocytic lesions | Histopathology |
| 14 | Rao, 2013 | J American Acad Dermatol | USA, Italy | Retrospective | 334 | 9 MMs, 27 BCCs, 43 SCCs | 98% | 44% | Dermoscopically equivocal melanocytic and non-melanocytic lesions | Histopathology |
| 15 | Longo, 2013 | Br J Dermatol | Italy | Retrospective | 140 | 32 MMs, 34 NMSCs | 96% | 94% | Dermoscopically equivocal nodular lesions | Histopathology |
| 16 | Guitera, 2012 | J Invest Dermatol | Italy, Australia | Retrospective | 710 | 216 MMs, 119 BCCs | 88% | 70% | Clinically/dermoscopically equivocal melanocytic and non-melanocytic lesions | Histopathology |
| 17 | Guitera, 2010 | J Invest Dermatol | Italy, Spain, Australia, USA | Retrospective | 219 | 81 LMs | 85% | 76% | Facial lesions | Histopathology |
| 18 | Guitera, 2009 | J Invest Dermatol | Italy, Australia | Retrospective | 326 | 123 MMs | 91% | 68% | Dermoscopically equivocal melanocytic lesions | Histopathology |
| 19 | Segura, 2009 | J American Acad Dermatol | Spain | Retrospective | 154 | 36 MMs, 27 BCCs | 100% | 57% | Dermoscopically equivocal melanocytic and non- melanocytic lesions | Histopathology |
| 20 | Langley, 2007 | Dermatology | Canada | 125 | 37 MMs | 97% | 83% | Clinically equivocal melanocytic lesion | Histopathology | |
| 21 | Pellacani, 2007 | J Invest Dermatol | Italy | Retrospective | 351 | 136 MMs | 92% | 69% | Dermoscopically equivocal melanocytic lesions | Histopathology |
| 22 | Pellacani, 2005 | J American Acad Dermatol | Italy | Retrospective | 102 | 37 MMs | 97% | 72% | Dermoscopically equivocal melanocytic lesions | Histopathology |
MM–melanoma, BCC–basal cell carcinoma, SCC–squamous cell carcinoma
Individual management performance of single reader evaluations.
| Reader number | Overall Sensitivity | Overall Specificity | MM sensitivity | BCC sensitivity | SCC sensitivity | Naevi | Spitz naevi specificity | SK/SK/ |
|---|---|---|---|---|---|---|---|---|
| 23/25 (92.0%) | 139/175 | 13/14 | 10/11 | N/A | 130/163 | 0/2 | 7/8 | |
| 31/33 | 125/167 | 15/17 | 16/16 | N/A | 112/146 | 0/4 | 13/16 | |
| 35/35 | 132/165 | 15/15 | 18/18 | 2/2 | 120/147 | 0/3 | 9/10 | |
| 41/42 | 132/158 | 14/14 | 24/25 | 3/3 | 116/138 | 0/2 | 9/10 | |
| 40/40 | 118/160 | 22/22 | 17/17 | 1/1 | 104/140 | 0/5 | 12/13 | |
| 34/37 | 128/163 | 13/15 | 20/21 | 1/1 | 113/143 | 0/2 | 12/15 | |
| 31/31 | 114/169 | 17/17 | 13/13 | 1/1 | 109/157 | 0/2 | 4/8 | |
| 36/37 | 109/163 | 20/20 | 15/16 | 1/1 | 99/144 | 0/5 | 7/10 | |
| 36/42 | 131/158 | 19/21 | 17/19 | 0/2 | 115/135 | 2/5 | 11/15 | |
| 28/30 | 129/170 | 9/11 | 18/18 | 1/1 | 116/153 | 0/2 | 9/11 | |
MM–melanoma, BCC–basal cell carcinoma, SCC–squamous cell carcinoma, SK–seborrheic keratosis, SL–solar lentigo, LPLK–lichen planus like keratosis, AK–actinic keratosis, R–reader, N/A–not applicable.
Overall management performance of double reader evaluation.
| Double NEGATIVE | Double NEGATIVE | Double NEGATIVE | 1 POS & 1 NEG | Double POSITIVE (0 x HC) | Double POSITIVE (1 x HC) | Double POSITIVE (2 x HC) | Total | |
|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 0 | 8 | 3 | 15 | 56 | ||
| 0 | 1 | 1 | 2 | 0 | 10 | 73 | ||
| 0 | 0 | 0 | 2 | 0 | 1 | 3 | ||
| 255 | 178 | 53 | 161 | 23 | 40 | 23 | ||
| 0 | 0 | 0 | 2 | 3 | 2 | 9 | ||
| 28 | 11 | 2 | 11 | 1 | 3 | 2 | ||
| 9 | 2 | 2 | 2 | 0 | 1 | 1 |
MM–melanoma, BCC–basal cell carcinoma, SCC–squamous cell carcinoma, SK–seborrheic keratosis, SL–solar lentigo, LPLK–lichen planus like keratosis, AK–actinic keratosis, HC–high confidence.
Fig 1ROC curve for double reading.
Reported frequencies of specific RCM features (based on 2000 evaluations).
| MM | BCC | SCC | Naevi (no spitz) | Spitz naevi | SK/SK/ | Other benign | |
|---|---|---|---|---|---|---|---|
| 140/166 | 1/174 | 0/12 | 297/1466 | 26/32 | 10/114 | 1/36 | |
| 133/166 | 0/174 | 0/12 | 243/1466 | 14/32 | 6/114 | 0/36 | |
| 4/166 | 155/174 | 2/12 | 7/1466 | 1/32 | 2/114 | 1/36 | |
| 13/166 | 17/174 | 7/12 | 8/1466 | 1/32 | 11/114 | 1/36 |
MM–melanoma, BCC–basal cell carcinoma, SCC–squamous cell carcinoma, SK–seborrheic keratosis, SL–solar lentigo, LPLK–lichen planus like keratosis, AK–actinic keratosis.